Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Gastro-enteropancreatic neuroendocrine tumor 2Pheochromocytoma 1Paraganglioma 1Neuroendocrine Tumors 1Metastatic Neuroendocrine Prostate Cancer 1

Interventions

Specimen Handling 4lutetium Lu 177 dotatate 3gallium Ga 68 dotatate 3Magnetic Resonance Spectroscopy 3olaparib 2cabozantinib 2belzutifan 2Temozolomide 2Nivolumab 2Fluorodeoxyglucose F18 2Biopsy 26-fluorodopamine 23-Iodobenzylguanidine 2tipifarnib 1talazoparib 1spartalizumab 1pembrolizumab 1pegfilgrastim 1lanreotide 1guadecitabine 1fluorodopa F 18 1fludarabine phosphate 1copper dotatate CU-64 1atezolizumab 1Stem Cell Transplantation 1Lutetium-177 1Lutetium 1Ipilimumab 1Interleukin-13 1Granulocyte Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pheochromocytoma × copper dotatate CU-64 × 1 year × Clear all
NCT04711135 2026-02-12

NETTER-P

Advanced Accelerator Applications

Phase 2 Active not recruiting
11 enrolled 14 charts 1 FDA
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡